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Missense mutation in the ATPase, aminophospholipid
transporter protein ATP8A2 is associated with
cerebellar atrophy and quadrupedal locomotion
Onur Emre Onat1,10, Suleyman Gulsuner1,10, Kaya Bilguvar2,3,4, Ayse Nazli Basak5, Haluk Topaloglu6,
Meliha Tan7, Uner Tan8, Murat Gunel2,3,4 and Tayfun Ozcelik*,1,9
Cerebellar ataxia, mental retardation and dysequilibrium syndrome is a rare and heterogeneous condition. We investigated a
consanguineous family from Turkey with four affected individuals exhibiting the condition. Homozygosity mapping revealed that
several shared homozygous regions, including chromosome 13q12. Targeted next-generation sequencing of an affected
individual followed by segregation analysis, population screening and prediction approaches revealed a novel missense variant,
p.I376M, in ATP8A2. The mutation lies in a highly conserved C-terminal transmembrane region of E1 E2 ATPase domain. The
ATP8A2 gene is mainly expressed in brain and development, in particular cerebellum. Interestingly, an unrelated individual has
been identified, in whom mental retardation and severe hypotonia is associated with a de novo t(10;13) balanced translocation
resulting with the disruption of ATP8A2. These findings suggest that ATP8A2 is involved in the development of the cerebro-
cerebellar structures required for posture and gait in humans.
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INTRODUCTION
Cerebellar ataxia, mental retardation and dysequilibrium syndrome
(CAMRQ) is a rare and genetically heterogeneous autosomal recessive
disorder characterized by mental retardation, cerebellar ataxia and
dysarthric speech with or without quadrupedal gait.1–8 Multiple
consanguineous families have been reported with autosomal
recessive inheritance of the condition. The first locus was mapped
to a 7.1-Mb region on chromosome 17p13 and a missense mutation
was reported on WDR81 (WD repeat domain 81; CAMRQ2; MIM:
610185; also referred to as Uner Tan syndrome).1,2,7 Linkage mapping
followed by candidate gene sequencing also led to the identification of
mutations in very low-density lipoprotein receptor (CAMRQ1; MIM:
224050)3–5 and carbonic anhydrase VIII (CAMRQ3; MIM: 613227).6
In another consanguineous family (Family C)3,9 from Turkey, the
involvement of VLDLR, WDR81 and CA8 genes were excluded, and
four shared-homozygous regions on chromosomes 13, 19 and 20 were
uncovered by homozygosity mapping. To identify the culprit gene, we
utilized targeted next-generation sequencing of all homozygous
regions and evaluated all co-segregated variants using functional
and structural predictions and population screening. We report herein
that a recessive missense mutation in ATP8A2, encoding ATPase,
aminophospholipid transporter, class I, type 8A, member 2, is
associated with the phenotype in Family C. In an independent
study, a de novo t(10;13) balanced translocation disrupting the
coding sequence of ATP8A2 on 13q12 was observed in a patient
with severe mental retardation and major hypotonia, raising the
possibility that haploinsufficiency of this gene could be implicated in
neurodevelopmental phenotypes.10 On the basis of these observations,
we suggest that ATP8A2 could be critically important in the
development of the nervous system.
SUBJECTS AND METHODS
Patients
The consanguineous family analyzed in this study has four members affected
by mental retardation, mild cerebellar and cerebral atrophy and truncal ataxia
(Figure 1). The index case was a 27-year-old man exhibiting total inability to
walk (05-993). Briefly, patients share the following clinical features: truncal
ataxia with/without quadrupedal gait, mental retardation and dysarthric
speech. MRI results revealed mild atrophy of cerebral cortex, corpus callosum
and inferior cerebellum. Clinical description of Family C was published
elsewhere.3,9 The only affected female in the family could not be included in
the study, as her parents did not give consent for DNA analysis. Case 05-993
recently died secondary to a respiratory infection. The study was approved by
the institutional review boards at the Baskent and Cukurova Universities
(decision KA07/47, 02.04.2007 and 21/3, 08.11.2005, respectively). Written
informed consent was obtained from all participants or their parents before
the study.
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Homozygosity mapping analysis
Participants’ DNA from peripheral blood samples were genotyped using 10 K
Affymetrix SNP chips. Experiments were performed according to the
manufacturer’s instructions (Affymetrix, Santa Clara, CA, USA). DNA of
two affected individuals (05-994 and 05-996) was genotyped using Illumina
Human610-Quad BeadChip according to manufacturer’s recommendations
(Illumina, Inc., San Diego, CA, USA). The image data were normalized and the
genotypes were called using data analysis software (Bead Studio, Illumina).
Homozygosity mapping analysis was performed using HomozygosityMapper
software.11 Homozygosity was ruled out for the previously reported loci.
Markers D13S787, D13S1243, D13S742, D13S283, D13S1294 and D13S221
were used to test homozygosity for the most likely candidate locus,
chromosome 13q12. Haplotype analysis was carried out by hand.
Mutation analysis
A total of 16 711 445 base long unique probes were designed to target
homozygous regions (Supplementary Table 1) using a custom-designed
Nimblegen Human Sequence Capture HD2 microarray (Roche NimbleGen,
Madison, WI, USA). DNA sample from an affected individual (05-996) was
captured using 3mg input DNA. Captured DNA sample was sequenced with
Illumina Genome Analyzer IIx. Illumina sequence data were mapped to
reference genome (hg18) using Maq12 and single-nucleotide variants were
determined with Samtools.13 To determine indels, data were mapped with
BWA14 and analyzed with Samtools. Variant coordinates were converted to
hg19 before publication by liftOver tool (http://genome.ucsc.edu/cgi-bin/
hgLiftOver). Coverage calculations of coding regions were done with
mpileup module of Samtools13 and intersectBED command of BEDTools.15
Novel variants were determined based on SNPs reported in dbSNP database
and further analyzed in 1000 genome data sets (http://www.1000genomes.org),
NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/, data
release ESP5400) and exome sequencing data of 2400 individuals with non-
neurological disorders generated at Yale University. Common variants were
excluded if minor allele frequency was lower than 0.1%. Novel variants were
confirmed by Sanger sequencing. Segregation analysis of the variants in the
pedigree and its presence in healthy population were carried out using allele-
specific PCR analysis (Supplementary Table 2). Racial distribution of control
group was 100% Caucasian, including 22% from southeastern Turkey.
Bioinformatics analysis
DNA and protein sequences were obtained from ENSEMBL database.16 SIFT,17
PolyPhen218 and MutationTaster19 tools were used to predict causative
variants. Genomic evolutionary rate profiling (GERP) and phylogenetic
P-value (phyloP) conservation scores for each variant were extracted
seperately from the UCSC Genome Browser allHg19RS_BW track20 and
phyloP46wayall track,21 respectively. Functional and transmembrane domains
of the ATP8A2 protein were predicted using Pfam database22 and TmPred
prediction tool (www.ch.embnet.org/software/TMPRED_form.html),
respectively. Homology searches were performed with CLCMain Workbench
(CLC Bio, Aarhus, Denmark) using appropriate modules. CLCMain
Workbench also generates phylogenetic tree using UPGMA algorithm that is
evaluated by bootstrap analysis. Possible effects of the variant on protein
secondary structure were predicted using PSIPRED server.23 Published
microarray data sets of E9.5, E11.5 and E13.5 mouse brain tissue
(GSE8091)24 were obtained from the GEO database (http://
www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi) and analyzed with
GeneSpring GX V11.1 software (Agilent Technologies, Santa Clara, CA,
USA). Differentially expressed genes within day groups were filtered (one-
way ANOVA test Bonferroni-corrected Po0.001) and genes that correlated
with Atp8a2 (R¼ 0.95–1.0) were functionally annotated using DAVID tools.25
Primers used in this study were designed with Primer326 software and are listed
in Supplementary Table 2.
Quantitative real-time RT-PCR
First-strand cDNAs were prepared from human RNA samples (Clontech,
Mountain View, CA, USA: 636567 (corpus callosum); Agilent: 540007
(cerebellum), 540117 (frontal cortex), 540137 (occipital cortex), 540157 (fetal
brain), 540053 (brain stem), 540005 (total brain), 540143 (parietal cortex),
540135 (striatum)) using RevertAid First Strand cDNA Synthesis kit with
random hexamer primers (Fermentas, now Thermo Fisher Scientific, Waltham,
MA, USA; K1622) after DNaseI (Fermentas EN0521) digestion. Real-time RT-
PCR was performed using IQ SYBR Green Supermix according to standard
protocols (BioRad, Hercules, CA, USA; 170-8882). Ct values were normalized
to GAPDH as an internal control. The data were analyzed using the Pfaffl
method.27
RESULTS
We identified four common homozygous regions in two affected
individuals (05-994 and 05-996) using Ilumina Human610-Quad
BeadChip. Targeted next-generation sequencing of all homozygous
regions (Supplementary Figure 1 and Supplementary Table 1) was
carried out using DNA of one affected individual (05-996). This
region was enriched 629-fold in the capture experiment. In total,
48.62 million single-end 75 bp reads were obtained and 29.2% of the
reads mapped to the targeted regions. This in turn provided a mean
coverage depth of 62.96-fold across the targeted homozygosity
intervals with 97.41% of the targeted bases being covered by at least
four reads (Supplementary Table 3). Next, the constitutive exons in
the homozygous intervals were analyzed and 99.51% of the protein
coding regions was found to be covered by at least four reads. When
the genes encoding for the constitutive exons in the low- or zero-
coverage regions were analyzed, they either do not have cerebellar
expression or do not display a phenotype compatible with cerebellar
involvement in mouse knockouts (Supplementary Table 4). On the
basis of these results, we find it highly unlikely that a causative
mutation is missed.
Figure 1 Pedigree of Family C with haplotype structure of the disease
interval on chromosome 13q12. Haplotype segregating with the disease is
boxed. ATP8A2 c.1128 C4G mutation is bold. Please note that the DNA of
one affected individual is not available for the study.
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A total of 14 103 homozygous variants (13 394 single-nucleotide
variants and 709 indels) were detected by next-generation sequencing.
Of these, 13 528 variants were reported by dbSNP132. Remaining 575
novel variants were classified by genomic context: protein altering or
flanking splice junctions (n¼ 11), coding synonymous (n¼ 4),
50-UTR (n¼ 44), 30-UTR (n¼ 30), intronic (n¼ 224) and intergenic
(n¼ 262). Of the 11 protein-altering variants, four were excluded
based on the comparison for novelty with 1000 genomes data, NHLBI
Exome Sequencing Project and the exome sequence data of 2400
individuals with non-neurological diseases. The remaining seven
variants in the coding regions of homozygous blocks were verified
by Sanger sequencing and four of them were excluded by segregation
analysis (Supplementary Figures 2–3). Two missense variants (ATP8A2
p.I376M and APBA3 p.A97T) and a 3-bp in-frame deletion (PCP2
p.E6del) were consistent with the recessive inheritance of the disease
allele in Family C (Table 1, Figure 1 and Supplementary Figure 2).
APBA3 p.A97T variant was excluded based on the conservation
considerations and prediction analyses. Four of 20 species sequenced
have threonine (T) at the orthologous site (Supplementary Figure 4),
suggesting that this variant would be a polymorphism and not
damaging to humans. A negative GERP score (4.11) for the
mutated nucleotide suggests that this site is probably evolving
neutrally.20 PhyloP score of the variant (0.308) suggests a faster
evolution than expected for this site.21 Furthermore, the variant was
predicted as ‘tolerated’ by SIFT17 (SIFT score, 0.16), ‘benign’ by
PolyPhen218 (PSIC score difference, 0.0) and ‘polymorphism’ by
MutationTaster19 (P-value, 0.999) (Table 1).
PCP2 p.E6del was excluded based on population screening. In 360
healthy chromosomes, four heterozygous individuals were identified
(Supplementary Figure 5), yielding an expected homozygote fre-
quency of approximately 1 in 8000. The region containing the
mutation is not conserved among species, and the deletion was
predicted as ‘polymorphism’ by MutationTaster19 (P-value, 0.717;
Table 1 and Supplementary Figure 6).
The remaining variant at chr13:26128001 (hg19; c.1128 C4G)
is located in exon 12 of ATP8A2 (ENSG00000132932,
ENST00000381655) and results in an isoleucine (I) to methionine
(M) substitution at residue 376. The mutation co-segregated with the
disease in Family C (Figure 1) lies in the C-terminal-predicted
transmembrane site of the E1 E2 ATPase domain (Figure 2a) and is
highly conserved across species (Figure 2b and Supplementary
Figure 7). Screening of 1210 control chromosomes, including 300
individuals from the same geographic region as Family C, excluded
presence of the variant in this control population. SIFT,17 PolyPhen218
and MutationTaster19 tools predicted the ATP8A2 p.I376M as a
causative mutation (scores: 0.0, 1.0 and 0.955, respectively).
Consequences of the amino acid change in protein structure were
evaluated by comparing the predicted secondary structures of wild-
type and mutant protein sequences. The wild-type protein is
predicted to contain 27 b-strands and 32 a-helices. I376 residue is
located at the N terminus of the 11th a-helix. The mutation enlarges
the 11th and 12th a-helices and creates an additional a-helix at
residue 401 (Figure 2c).
The status of ATP8A2 was evaluated in a cohort of 750 patients
with structural cortical malformations or degenerative neurological
disorders, and the underlying genetic cause is still unknown. Whole-
genome genotyping data generated by Illumina Human 370 Duo or
610K Quad BeadChips is available for this cohort. None of the
patients were found to harbor a homozygous interval (Z2.5 cM)
surrounding the ATP8A2 locus. Exome sequencing of the same group
did not reveal any mutations, including compound heterozygous
substitutions, in ATP8A2.
The transmembrane protein, ATP8A2, consists of four protein-
coding isoforms. The longest isoform (ENST00000381655) contains
37 exons and encodes a 112 kDa protein. The protein is highly
expressed in newborn and embryonic tissues, with strongest expres-
sion in mouse heart, brain and testis.10,28 RT-PCR analysis revealed
similar expression in different regions of the human brain.10 To
evaluate the possible involvement of ATP8A2 in motor functions, we
examined its expression profile in different human brain regions by
quantitative real-time RT-PCR. Human ATP8A2 is expressed in all
brain regions with the highest level of expression in cerebellum
(Figure 3). ATP8A2 expression in the patients cannot be evaluated, as
the gene is not expressed in lymphocytes.
To further investigate the role of ATP8A2 in brain development, we
examined the expression profiles of early embryonic mouse brain
(GSE8091)24 and identified genes with significantly correlated
expression profiles (R40.95, n¼ 218) with that of ATP8A2.
Functional clustering analysis suggested that positively correlated
genes were enriched for those involved in neuron differentiation,
cell, and neuron projection morphogenesis and axonogenesis
(Bonferroni-corrected P-values: 2.1E-3, 2.7E-3, 4.5E-3 and 1.5E-2
respectively). ATP8A2 is co-expressed with doublecortin responsible
for lissencephaly and WDR81 associated with CAMRQ2,7 suggesting
that these genes could represent similar developmental pathways.
DISCUSSION
CAMRQ is a rare genetically heterogeneous cerebellar ataxia with
mental retardation and dysarthric speech, with or without quad-
rupedal gait. Since the first mapping of the gene locus on chromo-
some 17p13, two additional loci on chromosomes 9p24 and 8q12
have been reported, and causative mutations have been identified in
VLDLR, CA8 and WDR81.2,3,6,7 Here we present the identification of
a fourth gene locus in a consanguineous family of two affected
Table 1 Novel coding variants identified by targeted next-generation sequencing of 05-996
Gene Position (hg19) Ref Var Effect GERP (score) PhyloP (score) SIFT (score) Polyphen2 (score) M. Taster (P-value) Segregation
ATP8A2 chr13:26,128,001 C G I376M 2.18 1.091 D. (0.02) P.D. (1.00) D.C. (0.995) Yes
APBA3 chr19:3,759,974 C T A97T 4.11 0.308 T. (0.16) B. (0.14) P. (0.999) Yes
MUC16 chr19:9,068,391 G A A6352V 1.45 0.803 n.a. n.a. P. (0.999) No
MUC16 chr19:9,068,577 G A T6290I 2.35 2.273 n.a. n.a. P. (0.999) No
ZNF823 chr19:11,833,601 A G C250R 0.632 1.532 D. (0.00) P.D. (1.00) P. (0.994) No
SERINC3 chr20:43,141,490 A G M116T 3.98 2.524 T. (0.34) B. (0.13) D.C. (0.999) No
PCP2 chr19:7,698,326 CTC — E6del n.a. 0.168 n.a. n.a. P. (0.717) Yes
Abbreviations: Ref, reference allele; Var, variant allele; M.Taster, Mutation Taster, D., damaging; T., tolerated; P.D., probably damaging; B., benign; n.a., not available; D.C., disease causing;
P., polymorphism.
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siblings and an affected nephew. Using whole-genome homozygosity
mapping followed by targeted next-generation sequencing, several
missense variants were observed. Filtering the variants by
co-segregation analysis, population screening, protein conservation
and disease gene prediction approaches revealed a novel missense
variant in ATP8A2 (c.1128 C4G; p.I376M) that segregates with the
phenotype. The mutation is located inside a transmembrane domain
and is predicted to change secondary structure of the protein.
ATP8A2 belongs to the P4-ATPases subfamily of P-type ATPases,
which are involved in the transport of aminophospholipids.
Biochemical studies have shown that P4-ATPases determine the
curvature of the phospholipid bilayer by flipping aminophospholipids
from the exoplasmic to the cytoplasmic leaflet.29,30 ATPases have been
implicated in human diseases such as ATP10C in Angelman
syndrome,31 ATP8B1 in hearing loss32 and hereditary cholestasis,33
and ATP8A2 in a severe neurological phenotype.10
ATP8A2 is involved in the transport of aminophospholipids toward
the cytoplasmic leaflet in brain cells, retinal photoreceptors and
testis.34 In humans, ATP8A2 is mainly expressed in brain tissues, with
highest levels in cerebellum, as well as in retina and testis.10
Cerebellum is a crucial regulatory organ for motor coordination
and this expression pattern is consistent with CAMRQ. The fact that
CAMRQ-associated genes have retinal expression34,35 raises the
possibility that eye abnormalities may be an additional clinical
feature of the phenotype. Strabismus has been observed in almost
all affected individuals in all the families reported thus far.1–8 In
addition, homozygous WDR81 mutation carriers display downbeat
nystagmus, temporal disk pallor and macular atrophy.36 However,
retinopathy is not a feature of WDR81-, VLDLR- and CA8-associated
CAMRQ.6,36 With respect to ATP8A2, further information is not
available, as Family C declined neuro-ophthalmological investigations.
Documentation of a de-novo-balanced translocation leading to
ATP8A2 haploinsufficiency10 brings into attention the clinical findings
of carriers in Family C. Whereas 05-992 and 05-995 did not
show neurological abnormalities, the t(10;13) de-novo-balanced
translocation carrier presented with a severe neurological phenotype
Figure 2 Graphical representation of the predicted functional and structural elements of ATP8A2 protein. (a) ATP8A2 is composed of an E1 E2 ATPase
domain and a haloacid dehalogenase-like hydrolase (HAD) domain. Ten transmembrane domains were predicted by TMPRED. The mutation lies in the
transmembrane region of C-terminal end of E1 E2 ATPase domain (dot). (b) Multiple amino acid sequence alignments show the sequence homology of
ATP8A2 protein in vertebrates. I376 residue is indicated with a box. (c) Graphical representation of secondary structural elements as predicted by
PSIPRED. The predicted elements (Pred) are indicated above the amino acid (AA) sequences (straight lines: coils; cylinders: helices; arrows: strands). The
mutation is predicted to alter the secondary structure of the protein. Transmembrane region is represented within the Pred graphs of wild-type (WT) and
mutant (Mut) proteins. EC, extracellular; IC, intracellular.
Figure 3 Expression pattern of ATP8A2 in nine different regions of human
brain. Real-time RT-PCR analysis showed that ATP8A2 is expressed in all
regions of the brain with the highest levels in the cerebellum.
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that partially overlaps with the phenotype of the affected members of
Family C. The possibility of a chimeric protein was ruled out, leaving
haploinsufficiency of ATP8A2 as the most likely explanation for the
phenotype. This suggests that ATP8A2 mutations represent yet
another example of clinical heterogeneity in the context of genomic
understanding of complex traits in humans and demonstrates
fundamental features of genomic analysis of human traits such as
variable expression, allelic heterogeneity and genotype–phenotype
correlations. Other examples include CRYBB1 in congenital cataract,37
COLL11A2 in Zweymuller Weissenbacher syndrome38 and MYBPC1
in arthrogryposis.39
These findings suggest that ATP8A2 could be critical for the
developmental processes of central nervous system, and alterations
of this gene may lead to severe neurological phenotypes.
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